Diffuse Large B Cell Lymphoma Market

DelveInsight's “Diffuse Large B-cell Lymphoma - Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the DLBCL, historical and forecasted epidemiology as well as the DLBCL market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

DLBCL market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM DLBCL market size from 2019 to 2032. The report also covers current DLBCL treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain), and the United Kingdom
• Japan

Study Period: 2019-2032

Diffuse Large B-cell Lymphoma Disease Understanding and Treatment Algorithm

Diffuse Large B-cell Lymphoma Overview

Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive (fast-growing) and the most common type of non-Hodgkin’s lymphoma that can arise in lymph nodes or outside of the lymphatic system (such as in gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain). Often, the first sign of DLBCL includes painless, rapid swelling in the neck, underarms, or groin that is caused by enlarged lymph nodes. For some patients, the swelling may be painful. Other symptoms may include night sweats, fever, and unexplained weight loss. Patients may notice fatigue, loss of appetite, shortness of breath, or pain. Generally, it has been observed that DLBCL affects patients of all age groups with a wide range of presentations concerning localization, morphology, and molecular mechanisms.

There are several subtypes of DLBCL. Classification of the DLBCL subtype requires examination of cell morphology (shape, structure, and form) as well as specialized tests including immunohistochemistry, flow cytometer, fluorescence in situ hybridization (FISH) and molecular testing.

WHO/REAL classification

1. DLBCL, not otherwise specified (NOS):

• T-cell/histiocyte rich large B-cell lymphoma
• Primary DLBCL of the central nervous system (CNS)
• Primary cutaneous DLBCL, leg type
• Epstein-Barr virus (EBV)-positive DLBCL of the elderly
• Germinal center B-cell (GCB)-DLBCL
• Activated B-cell (ABC)-DLBCL

2. DLBCL associated with chronic inflammation:

• Primary mediastinal lymphoma
• Intravascular large B-cell lymphoma
• Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma

Diffuse Large B-cell Lymphoma Diagnosis

A tissue biopsy is needed for a definitive diagnosis of DLBCL. Because DLBCL is a blood cancer, it is important to look for any signs of lymphoma across the entire body. This is usually done with a positron emission tomography (PET) scan. A morphological diagnosis of DLBCL should be confirmed in all cases by immunophenotypic investigations, either immunohistochemistry (IHC) or flow cytometry or a combination of both techniques.

Diffuse Large B-cell Lymphoma Treatment

DLBCL treatment is typically begun shortly after diagnosis with the intent of obtaining a durable remission or cure. A combination of chemotherapy and a monoclonal antibody targeting CD20 remains the backbone of most treatments. The most widely used combination chemotherapy regimen for DLBCL is R CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) that is usually given in 21-day cycles. Sometimes etoposide (VePesid, Toposar, Etopophos) is added to the R-CHOP regimen, resulting in a drug combination called R-EPOCH. Sometimes treatment may involve radiation therapy. For many patients with DLBCL, the initial treatment can lead to disease remission (disappearance of signs and symptoms). However, for patients in whom the disease becomes refractory (no longer responds to treatment) or relapses (returns after treatment), secondary therapies may be successful.

Diffuse Large B-cell Lymphoma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total incident population of DLBCL, gender-specific population of DLBCL, age-specific population of DLBCL, type-specific population of DLBCL, and stage-specific population of DLBCL in the 7MM market covering the United States, EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032.

Key Findings

This section provides glimpse of the DLBCL epidemiology in the 7MM

Country Wise- Diffuse Large B-cell Lymphoma Epidemiology

The epidemiology segment also provides the DLBCL epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

• The total incident population of DLBCL in the 7MM comprised of 73,598 cases in 2021 and are projected to increase during the forecast period.
• The total incident population of DLBCL in the United States is 29,958 in 2021.
• The United States contributed to the largest incident population of DLBCL, accounting for ~ 41% of the 7MM in 2021.
• Among EU4 countries, Germany accounted for the highest number of DLBCL cases, whereas Spain accounted for the lowest cases in 2021.
• In Japan, the total incident population of DLBCL was 11,409 in 2021 and is anticipated to rise during the forecast period.
• Among the total 26,064 cases of DLBCL, NOS type in 2021 in the US, GCB subtype accounts for 11,983 cases while ABC subtype accounts for 17,975 cases.
• In 2021, males and females accounted for 16,777 and 13,182 cases respectively in the United States.
• In 2021, the total cases of DLBCL in Stage I, Stage II, Stage III, and Stage IV were identified to be 7,190, 5,992, 5,093, and 11,684

DLBCL Drug Chapters

Drug chapter segment of the DLBCL report encloses the detailed analysis of DLBCL marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the DLBCL clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

YESCARTA (axicabtagene ciloleucel): Kite Pharma (a subsidiary of Gilead Sciences)

YESCARTA is a CD19-directed genetically modified autologous T-cell immunotherapy. In April 2022, Kite announced that FDA has approved YESCARTA for adult patients with LBCL that is refractory to first-line chemo immunotherapy or that relapses within 12 months of first-line chemo immunotherapy. In October 2017, the FDA granted approval to YESCARTA for treating adult patients with R/R LBCL after two or more lines of systemic therapy. In October 2022, Gilead announced that European Commission has approved the use of YESCARTA to treat adult patients with DLBCL and HGBL who relapse within 12 months from completion of or are refractory to, first-line chemo immunotherapy. The company is planning to file the application for YESCARTA in 1L setting on the basis of ZUMA-23 in 2025 or beyond.

KYMRIAH (tisagenlecleucel): Novartis

KYMRIAH is a CD19-directed genetically modified autologous T-cell immunotherapy comprised of autologous T cells that are genetically modified using a lentiviral vector to encode an anti-CD19 chimeric antigen receptor. KYMRIAH is approved for treating adult patients with R/R LBCL after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

XPOVIO (selinexor): Karyopharm

XPOVIO, is a first-in-class, oral selective inhibitor of nuclear export (SINE) compound. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus. The FDA granted accelerated approval to XPOVIO for adult patients with R/R DLBCL, not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy. In November 2018, Karyopharm’s selinexor received FTD from FDA to treat patients with R/R DLBCL.

POLIVY (polatuzumab vedotin-piiq): Roche/Chugai Pharmaceuticals

POLIVY (polatuzumab vedotin-piiq) is a CD79b-directed antibody-drug conjugate (ADC) consisting of three components: the humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b; the small molecule anti-mitotic agent MMAE; and a protease-cleavable linker maleimidocaproyl-valine-citrulline-p-amino benzyloxy carbonyl (mc-VC-PAB) that covalently attaches MMAE to the polatuzumab antibody. In June 2019, the US FDA granted accelerated approval to POLIVY (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (known as “BR”), to treat adult patients with DLBCL that has progressed or returned after at least two prior therapies. In the May 2022, POLIVY combination received EU approval for previously untreated DLBCL.

Note: Detailed current therapies assessment will be provided in the full report of DLBCL

Emerging Drugs

Epcoritamab: AbbVie and Genmab

Epcoritamab (also known as GEN3013) is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. Epcoritamab is being codeveloped by AbbVie and Genmab as part of the companies’ oncology collaboration. The companies will share commercial responsibilities in the US and Japan, with AbbVie responsible for further global commercialization. In October 2022, AbbVie announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab to treat adult patients with R/R DLBCL after two or more lines of systemic therapy. In November 2022, AbbVie announced that the US FDA has accepted for priority review the Biologics License Application for epcoritamab, to treat adult patients with relapsed/refractory LBCL after two or more lines of systemic therapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of May 21, 2023.

Glofitamab: Roche

Glofitamab (CD20-TCB, RG6026) is an investigational CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. Roche filed for approval of glofitamab in April 2022 in the EU for 3L DLBCL. Findings from the expansion study, known as NP30179, have been submitted to the European Medicines Agency (EMA). An application to the FDA in the United States is planned for the end of 2022. According to the company, data readout from the Phase III glofitamab + GemOx (STARGLO) trial in 2L+ DLBCL is expected by 2023/2024. The company anticipates submission to health authorities for glofitamab + chemotherapy in 2L DLBCL by 2024 and glofitamab + chemotherapy in 1L circulating tumor (ct) DNA+ high-risk DLBCL by 2025 and beyond.

ALLO-501A: Allogene Therapeutics

ALLO-501A, a next-generation anti-CD19 Allo CAR-T, is engineered without the rituximab recognition domains included in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure; AALLO-501A uses the Cellectis TALEN technology. In October 2022, the company initiated the Phase II clinical trial of ALLO-501A (the ALPHA2 trial) in patients with R/R LBCL. The company is also in the process of initiating the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the lymphodepletion regimen. Allogene is also conducting a long-term follow-up in the Phase I clinical trial (the ALPHA trial) of ALLO-501 in patients with R/R NHL. Assuming favorable outcomes and subject to FDA discussions, the company plans to seek FDA approval of ALLO-501A based on the ALPHA2 trial. According to the company, the readiness of the Phase II (ALPHA3) trial of ALLO-501A is expected by 2023. Target enrollment completion of the ALPHA2 trial is expected by 1H 2024

LUNSUMIO (mosunetuzumab): Roche and Biogen

LUNSUMIO (mosunetuzumab, RG7828) is a first-in-class CD20 x CD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. In July 2022, Roche announced that the US FDA has accepted the company’s Biologics License Application (BLA) and granted Priority Review for LUNSUMIO to treat adults with R/R FL who have received at least two prior systemic therapies. Currently, Roche is investigating the LUNSUMIO plus POLIVY in Phase III (SUNMO) trial in 2L DLBCL, with most trial locations outside the 7MM except for Japan. With an expected submission in the US by 2025 and beyond and by 2024 in Japan, as per Chugai Pharmaceutical.

Zamtocabtagene autoleucel (MB-CART2019.1): Miltenyi Biomedicine

Zamtocabtagene autoleucel (MB-CART2019.1) targets the combination of CD19 and CD20 proteins in B cells. This investigational therapy candidate has been selected for the PRIority MEdicines scheme (PRIME) in the European Union. Additionally, the company has submitted an Investigational New Drug (IND) application for a new CAR T-cell therapy to the FDA in the United States. Promising results from 2-year follow-up data from the Phase I/II trial of zamtocabtagene autoleucel, DALY 1 (NCT03870945) in elderly patients with R/R DLBCL at the EHA 2022, represent the rationale for the ongoing randomized Phase II trials, DALY 2-EU (NCT04844866) and DALY 2-US (NCT04792489). DALY 2-EU is currently enrolling and investigating the superiority of MB-CART2019.1 over conventional immunochemotherapy in older patients with R/R DLBCL who are not eligible for high-dose chemotherapy or autologous stem cell transplantation. DALY 2-US is currently enrolling and investigating MB-CART2019.1 in adults with R/R DLBCL after receiving at least two lines of therapy.

Note: Detailed emerging therapies assessment will be provided in the final report.

DLBCL Market Outlook

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma for which a cure is usually the therapeutic goal of optimal treatment. There are several treatment options for DLBCL, which include chemotherapy, radiation, and immunotherapy. The aforementioned treatment modalities have been used, alone or in combination, in the last decades to treat DLBCL. Chemotherapy is the main way to treat DLBCL.

The market growth over the forecast period is also being driven by an increase in pipeline candidates for the development of therapies for better recovery of DLBCL. Rituximab's approval altered the DLBCL therapeutic landscape. For DLBCL patients, chemo immunotherapy is the standard of care. In addition, numerous drugs that have recently been approved have transformed the treatment landscape for individuals with R/R DLBCL in 2L and 3L.

In recent years, the FDA has approved seven new therapies in the R/R DLBCL setting across a range of different modalities including CAR-T therapies, small molecules, monoclonal antibodies and antibody-drug conjugates.

The notable and exponential understanding of cellular processes that are deregulated during lymphomagenesis, such as signal transduction pathways, transcriptional and translational regulation, protein stability and degradation, cell cycle regulation, and mitosis and apoptosis, as well as the study of the microenvironment has led to the discovery and progress of new targeted therapies.

Many novels targeted agents under trial are being tested in double-hit lymphoma including the BCL2 inhibitor, PI3K inhibitor, and an mTOR inhibitor. The INKa/ARF deletion causes genomic instability. Constitutive activation of NFkB is being targeted in several trials of proteasome inhibitors, immunomodulatory agents, and B cell receptor signaling pathway inhibitors.

There is currently no therapy approved for patients who have failed CAR-T. Moreover, current NCCN treatment guidelines suggest a variety of treatment options for patients in second or later relapse who previously received CAR-T, including clinical trial participation, alternative second-line chemotherapy (but the guidelines note patients are unlikely to derive benefit from this approach), palliative radiation therapy, or best supportive care. There is no established standard of care for treating adults with DLBCL once a CAR-T treatment fails, thus highlighting the need for new, efficient therapeutic options.

Even though the reimbursement of CAR-T therapies represents a challenge for healthcare providers, insurers, and government agencies, have successfully reached the majority of the markets by considering the patient pool demand. While determining the cost and reimbursement, various factors such as pharmacoeconomic analysis and outcome-based responses, as well as the added value to society have been evaluated. The CAR T-cell-related toxicity such as the cytokine-release syndrome and neurotoxicity remain important potential complications of this therapy. To overcome these limitations second generations CAR T-cell therapies are emerging with more safety and efficacy. If these limitations have been overcome, these are going to be the potential drivers of the market.

The DLBCL pipeline possesses multiple potential drugs in late- and mid-stage developments to be launched shortly. Key players involved in robust research and development include enzastaurin, ADCETRIS, epcoritamab, LUNSUMIO, glofitamab, zilovertamab vedotin, maveropepimut-S, plamotamab, mivavotinib, zamtocabtagene autoleucel, ALLO-501A, and others in combination with other therapies or as a monotherapy are some of the major players that are going to alter the market dynamics in the coming years.

Key Findings

This section includes a glimpse of the DLBCL in 7MM market.

• The total market size of DLBCL in the 7MM is USD 3,700 million in 2021 and is projected to grow during the forecast period (2022-2032).
• According to the estimates, the highest market size of DLBCL is from the United States, in 2021 and is anticipated to grow at a CAGR of 10.4%.
• Among EU4 countries, Germany has the maximum revenue share in 2021 while Spain has the lowest market share.
• The market size of DLBCL in Japan is USD 448 million in 2021 which is expected to rise during the forecast period (2022-2032).

The United States Market Outlook

The total market size of DLBCL in the United States is expected to increase with a CAGR of 10.4% during the study period (2019–2032).

EU4, the UK Market Outlook

The total market size of DLBCL in EU4 and the UK is expected to increase with a CAGR of 10.2% during the study period (2019–2032).

Japan Market Outlook

The total market size of DLBCL in Japan is expected to increase with a CAGR of 8.6% during the study period (2019–2032).

Analyst Commentary

• DLBCL has an active pipeline as many pharmaceutical companies are working towards developing an effective and affordable therapy in first-line, first-R/R transplant-eligible, first-R/R transplant-ineligible, and subsequent R/R setting.
• Generic chemotherapy is still the treatment backbone of all B-cell NHL subtypes. Although the addition of rituximab improved outcomes in patients with B-cell lymphomas, a significant number of patients are rituximab refractory at the time of relapse.
• A new standard of care for the first-line treatment of DLBCL, potentially reducing the need for subsequent treatments and limiting the patient burden, is the need of the hour. As POLIVY is not expected to be approved until April 2023, trends in the first-line DLBCL market remain stable, dominated by RITUXAN-based combinations, particularly R-CHOP.
• YESCARTA appears to have the upper hand in the battle for CAR-T supremacy in the first-R/R transplant eligible setting given it has been in the market before BREYANZI.
• There are also many earlier-stage approaches to DLBCL treatment, including next-generation CD19xCD3 specifics, allogenic CD19 CAR-T, next-generation CD19 CAR-T, CD47 targeting agents, and other targets. Through time, it is expected that trials of novel combinations with the CD3xCD20 class to be initiated, which could further broaden the array for 2L DLBCL treatment.
• When bispecific antibodies are compared to CAR-T cells, an advantage of the patient’s immune system can be taken in the case of bispecific antibodies.
• CAR-T therapies need intricate manufacturing procedures, requiring more than 2 weeks before the finished product is delivered to the patient for infusion. Additionally, patients must travel to the designated large treatment centers to get CAR-T treatment. But, some drugs are readily available as off-the-shelf therapy, which do not require any wait for the people to start the treatment.

DLBCL Drugs Uptake

This section focuses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2019-2032. The analysis covers DLBCL market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Epcoritamab which is an investigational IgG1-bispecific antibody created using Genmab’s proprietary DuoBody technology. In November 2022, AbbVie announced that the US FDA has accepted for priority review the Biologics License Application for epcoritamab, to treat adult patients with relapsed/refractory LBCL after two or more lines of systemic therapy. Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of May 21, 2023. In October 2022, AbbVie announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab to treat adult patients with R/R DLBCL after two or more lines of systemic therapy. As per our analysis, epcoritamab drug uptake in the US for subsequent R/R DLBCL is expected to be medium with a probability adjusted peak share of 13%, years to peak would be 6 years.

DLBCL Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for DLBCL emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders from UT Southwestern Medical Center in Dallas, Cancer Research UK Barts Centre in London, MD Anderson Cancer Center. Their opinion helps to understand and validate current and emerging therapies treatment patterns or DLBCL market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the DLBCL market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of DLBCL, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
• Comprehensive insight has been provided into the DLBCL epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for DLBCL are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of DLBCL market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM DLBCL market.

Report Highlights

• In the coming years, DLBCL market is set to change due emerging therapies in the pipeline, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence DLBCL R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• As per DelveInsight’s analysis the major types of DLBCL include diffuse large B-cell lymphoma, NOS, germinal center B-cell-like or GCB subtype, non-GCB types, usually activated B-cell-like (ABC subtype), and others.
• The report also encompasses other major segments, i.e., total incident population of DLBCL, gender-specific population of DLBCL, age-specific population of DLBCL, type-specific population of DLBCL, and stage-specific population of DLBCL.
• Expected launch of potential therapies such as Epcoritamab (AbbVie and Genmab), Zilovertamab vedotin (Merck), Glofitamab (Roche), Plamotamab (Xencor and Janssen), Zamtocabtagene autoleucel (Miltenyi Biomedicine), and others might change the landscape in treatment of DLBCL.
• The US FDA-approved drugs which are currently available include RITUXAN/MABTHERA, YESCARTA, KYMRIAH, XPOVIO, POLIVY, and others.

DLBCL Report Insights

• DLBCL Report Insights
• Patient Population
• Therapeutic Approaches
• DLBCL Pipeline Analysis
• DLBCL Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

DLBCL Report Key Strengths

• Eleven Years Forecast
• 7MM Coverage
• DLBCL Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

DLBCL Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• SWOT
• Attribute Analysis

Key Questions

Market Insights:

• What was the DLBCL market share (%) distribution in 2019 and how it would look like in 2032?
• What would be the DLBCL total market size as well as market size by therapies across the 7MM during the study period (2019–2032)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest DLBCL market size during the study period (2019–2032)?
• At what CAGR, the DLBCL market is expected to grow at the 7MM level during the study period (2019–2032)?
• What would be the DLBCL market outlook across the 7MM during the study period (2019–2032)?
• What would be the DLBCL market growth till 2032 and what will be the resultant market size in the year 2032?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of DLBCL?
• What is the historical DLBCL patient pool in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• What would be the forecasted patient pool of DLBCL at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to DLBCL?
• Out of the above-mentioned countries, which country would have the highest incident population of DLBCL during the study period (2019–2032)?
• At what CAGR the population is expected to grow across the 7MM during the study period (2019–2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the treatment of DLBCL? What are the current treatment guidelines for the treatment of DLBCL in the US and Europe?
• What are the DLBCL marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of DLBCL?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of DLBCL?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DLBCL therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for DLBCL and their status?
• What are the key designations that have been granted for the emerging therapies for DLBCL?
• What are the 7MM historical and forecasted market of DLBCL?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the DLBCL.
• To understand the future market competition in the DLBCL market and Insightful review of the SWOT analysis of DLBCL.
• Organize sales and marketing efforts by identifying the best opportunities for DLBCL in the US, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for DLBCL market.
• To understand the future market competition in the DLBCL market.